Drug Profile
Research programme: nucleotide therapeutics - enGene
Alternative Names: EG 10; EG-02; EG-12; GEMS™-InsulinLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator enGene
- Developer enGene; Janssen Biotech
- Class DNA; Nucleotides; Proteins; RNA
- Mechanism of Action Glucagon receptor antagonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Coeliac disease; Cystitis; Diabetes mellitus; Inflammatory bowel diseases
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in Canada (Intraduodenal, Spray)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in Canada
- 04 Nov 2017 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in Canada